Company Overview
TELA Bio, Inc. operates as a commercial-stage medical technology entity dedicated to delivering soft-tissue reconstruction solutions designed to optimize clinical outcomes through the prioritization of patient anatomy preservation and restoration. The company functions within the Healthcare sector, specifically inside the Medical Devices industry, where it aims to address critical needs in surgical reconstruction and tissue management. Currently, TELA Bio maintains a market capitalization of $29.98M and generates annual revenue of $80.28M, while the specific employee count is not disclosed in the provided data. These financial figures indicate that TELA Bio is a relatively small-cap enterprise with a significant revenue stream relative to its size, suggesting a focus on high-value, specialized medical product lines that drive substantial top-line growth without the scale of large-cap competitors.
Financial Health
The company reported revenue of $80.28M over the trailing twelve months, accompanied by a net income loss of $-38,831,000 and an EBITDA of $-32,708,334, revealing a substantial gap between top-line revenue generation and bottom-line profitability that highlights a heavy cost structure or significant investment in R&D and operations. Although specific free cash flow figures are not listed, the cash position stands at $50.84M while total debt amounts to $57.13M, presenting a scenario where liquid assets do not fully cover short-term obligations without considering the broader debt profile. The gross margin stands at 68.2%, indicating strong pricing power or efficient manufacturing relative to the cost of goods sold, whereas the operating margin of -31.9% and profit margin of -48.4% demonstrate that operating expenses and interest costs are significantly eroding the gross profit. The balance sheet shows a debt-to-equity ratio of 904.96, signaling a highly leveraged capital structure where debt obligations are nearly ten times the equity base. Despite the high leverage, the current ratio of 4.21 suggests robust short-term liquidity, as current assets are more than four times the value of current liabilities, providing a buffer against immediate payment demands. Furthermore, the return on equity is -223.4% and the return on assets is -25.1%, metrics that reveal management is currently generating negative returns on the capital invested, reflecting the company's stage of development or the challenges of scaling a new medical technology portfolio.
Valuation Assessment
Valuation metrics for TELA Bio present a complex picture given the lack of normalized earnings, with the trailing P/E ratio listed as N/A and a forward P/E of -1.19, implying that the market is pricing the stock based on future earnings expectations that are currently negative or that traditional multiple analysis is not applicable due to the loss-making status. The price-to-book ratio is 4.72, which indicates that the market values the company at a significant premium over its tangible book value, potentially reflecting confidence in the intangible assets, intellectual property, or future growth potential of the medical device portfolio. Alternative valuation metrics include a price-to-sales ratio of 0.37 and an EV/EBITDA of -1.10, suggesting that the market is valuing the company primarily on its revenue generation capabilities rather than current profitability or earnings multiples. The stock has traded between a 52-week low of $0.63 and a 52-week high of $2.20, with the current price implied to be situated within this range, though the exact current price is not provided to calculate the precise percentage distance from these extremes. The beta value is 0.89, indicating that the stock's price volatility is slightly lower than the broader market, suggesting it may be less sensitive to general market swings compared to the average stock in the index.
Growth & Income
TELA Bio has demonstrated robust revenue expansion with a year-over-year growth rate of 18.2%, whereas earnings growth is listed as N/A due to the company's negative net income, implying that the business is prioritizing revenue scaling and market penetration over immediate profit generation. As a non-dividend payer, the company does not distribute a dividend yield, maintaining a payout ratio of 0.0%, which means all available earnings are theoretically available for reinvestment into operations, though current losses necessitate the use of cash reserves or debt financing for growth initiatives rather than dividend distribution. The absence of a dividend yield and the presence of negative earnings growth highlight a growth-oriented profile where capital is directed toward expanding the soft-tissue reconstruction business rather than returning cash to shareholders. Overall, the company presents a high-growth, non-income profile characterized by strong revenue momentum but significant financial losses and a leveraged balance sheet typical of early-to-mid stage medical technology firms.